Understanding the costs of drug-related actions is an important aspect of drug policy.
In Malta, the financing of drug-related activities is decided annually by the entities in charge of their implementation. The available information is very limited and does not permit reporting on the size and trends of drug-related expenditure.
The most recent estimate, for 2012, suggests that drugrelated expenditure represented approximately 0.08 % of gross domestic product, that is, Malta spent an estimated EUR 5.5 million on drug reduction activities. However, it is not known what proportion of all drug-related expenditure this represents.